Prophylaxis for Immunocompromised Patients

The Future in the Fight Against COVID-19 is HERE

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab). Evusheld is a potent new COVID-19 protective measure (monoclonal antibody) designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals who may not mount an adequate immune response to COVID-19 vaccination.

Think you are eligable to receive Evusheld? Talk to your provider today and ask for a prescription.

Are you a Healthcare Provider?

Access the Prescription Order Form and Resource Page for more information

FAX: (405) 454-7611 Phone: (405) 805-6191

What is Evusheld?

In immunocompromised patients, a vaccination may not generate enough immune response, so they are still vulnerable to severe infection. Evusheld gives additional immunity to help prevent COVID-19.

Evusheld is a combination of two monoclonal antibodies, given in two consecutive injections in one visit to qualifying patients who do not have COVID-19.

How is it Administered?

Evusheld is administered by giving two shots by intramuscular (IM) injection in the gluteal region injecting one shot right after the other.

A one hour monitoring period will follow after administration so you can expect the entire process to take 75-90 minutes.

Who is Eligable?

Adults and pediatric individuals (12 years of age and older weighing at least 88 pounds 40 kg):

  • Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2, AND:

    • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, OR

    • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

Learn More About EVUSHELD

EVUSHELDTM long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

Learn About Evusheld and Protecting Patients with Compromised Immune Systems

How Does a Mobile Monoclonal Antibody Appointment Work?

If you do qualify, consent and have a valid prescription; an appointment will be booked and payment will be made at that time. Our goal is to administer Evusheld same day when we have the therapy available including weekends.

This is a Mobile appointment, we will bring the medication to you and administer in the convenience of your home.

Please note that this is ONLY for pre-exposure prophylaxis (you have not been exposed) to COVID-19. Please note that a negative COVID-19 Test is required to receive this medication per our policy. A Rapid Antigen Test will be preformed as part of our service.

If you do not currently have a prescription, we can work with your doctor's office; please give us a call.

We are not credentialed with insurance companies, so you may choose to private pay the $300 charge and ask for reimbursement from your insurance. You will be provided a Superbill to ask for reimbursement from your insurance.